Make Your First AppointmentGet a Second Opinion
Call us: 877-442-3324
The Gynecologic Oncology Program at the Susan F. Smith Center for Women's Cancers at Dana-Farber is committed to providing expert, compassionate care for patients with gynecologic cancers, including cervical cancer, endometrial/uterine cancer, gestational trophoblastic disease, ovarian cancer, vaginal cancer and vulvar cancer. Because gynecologic cancers can have a wide range of physical and emotional effects, we offer multi-dimensional services to strengthen mind, body, and soul for our patients and their families. You are not alone in this journey.
Donna GregoryCancer patient
We want to keep you fully informed about all that's happening at the Susan F. Smith Center for Women's Cancers at Dana-Farber. Read about our latest progress in gynecologic cancer research, see media coverage of our gynecologic cancer researchers and clinicians, read blog posts on a variety of topics pertaining to gynecologic cancer.
May 25, 2015Dana-Farber is part of the Massachusetts Coalition for HPV/Cervical Cancer Awareness, which works to increase and follow HPV vaccination rates in the state.
May 4, 2015Dr. Ursula Matulonis commented on the FDA’s approval of olaparib, a drug on which she led a study for ovarian cancer.
May 1, 2015Dr. Beth Overmoyer commented on the importance of genetic testing following Angelina Jolie’s had her breasts, ovaries and fallopian tubes removed after genetic tests revealed a mutation in the BRCA1 gene.
April 21, 2015Dr. Ursula Matulonis presented data at the American Association for Cancer Research Annual Meeting, which showed combination treatment with the poly ADP-ribose polymerase inhibitor olaparib and the investigational phosphatidylinositol-3-kinase inhibitor BKM120 was safe and yielded evidence of clinical benefit for women with triple-negative breast cancer and for those with high-grade serous ovarian cancer.
April 21, 2015Dana-Farber researchers report that combination treatment with olaparib and BKM120 was safe and yielded evidence of clinical benefit for women with triple-negative breast cancer and for those with high-grade serous ovarian cancer in a phase I clinical trial.
April 20, 2015Dana-Farber's Alan D'Andrea, MD, has been selected to lead a Stand Up To Cancer Dream Team devoted to ovarian cancer research. The team will focus on DNA repair therapies for ovarian cancer.
March 24, 2015Dr. Judy Garber, director of Dana-Farber's Center for Cancer Genetics and Prevention, commented on actress Angelina Jolie’s decision to have her ovaries and fallopian tubes removed for preventive measures.
March 24, 2015Dr. Huma Rana, from Dana-Farber's Center for Cancer Genetics and Prevention, commented on actress Angelina Jolie’s decision to have her ovaries and fallopian tubes removed for preventive measures.
March 24, 2015Dr. Ursula Matulonis, medical director of gynecologic oncology at Dana-Farber, commented on actress Angelina Jolie’s decision to have her ovaries and fallopian tubes removed for preventive measures.
March 4, 2015Dr. Panagiotis (Panos) Konstantinopoulos was mentioned for his collaboration on an article, published in Genes & Development, that used an innovative genome-wide RNA screen to determine why so many instances of ovarian cancers develop resistance to the cancer drug cisplatin.
February 16, 2015Dr. Ursula Matulonis discussed the FDA approval of olaparib (Lynparza) for the treatment of women with BRCA-positive advanced ovarian cancer.
February 13, 2015A study by Dana-Farber Cancer Institute scientists indicates that the pool of patients who can benefit from the drug olaparib is potentially much wider — and offers a ready means of identifying them.
December 19, 2014Dr. Ursula Matulonis commented on the US Food and Drug Administration’s approval of Lynparza as the first monotherapy for patients with BRCA-mutated advanced ovarian cancer, but only for those who have received three or more prior lines of chemotherapy.
November 13, 2014Dr. Ursula Matulonis commented on early detection of ovarian cancer, which was a topic of focus at the Susan F. Smith Center for Women’s Cancers Executive Council Luncheon.
November 4, 2014Dr. Alexi Wright led a study on the use of hospice in the final days of ovarian cancer.
October 27, 2014Dr. Alexi Wright's research on the use of hospice in the final days of ovarian cancer has been published in the Journal of Clinical Oncology.
October 22, 2014Dr. Alexi Wright led a study that found increasing the use of hospice in the final days of ovarian cancer does not offset intensive end-of-life care in older women.
October 15, 2014As more terminally ill patients choose to spend their final days and weeks in hospice care rather than a hospital, the hope is the use of intensive and costly hospital services would decline. A new study by Dana-Farber researchers shows for one group of terminally ill cancer patients, that is not what is happening.
October 14, 2014A new study by researchers at Dana-Farber shows a half-day educational program can help women successfully deal with side effects of ovary removing surgery as a cancer prevention measure.
September 17, 2014As reported in The Lancet Oncology, Dr. Joyce Liu led a randomized phase 2 trial that found a significant improvement in progression-free survival and an increase in toxicity with the addition of a antiangiogenic agent to a PARP inhibitor in women with recurrent, platinum-sensitive ovarian cancer.
September 10, 2014Dr. Ursula Matulonis and Dr. Joyce Liu from the Susan F. Smith Center for Women’s Cancers report in the online edition of The Lancet Oncology that for some women with recurrent ovarian cancer, a new drug combination has been found to stall the progression of the disease.
September 5, 2014Dr. Ursula Matulonis, Medical Director of GYN Oncology at the Susan F. Smith Center for Women's Cancers, was featured with her patient, Beverly, during the fourth Biennial Stand Up 2 Cancer telecast, which aired on all major television networks on Friday night.
August 20, 2014Dr. Panos Konstantinopolous, a medical oncologist at the Susan F. Smith Center for Women’s Cancers Gynecologic Oncology program, comments on Dana-Farber’s team approach to patient care during the 13th annual WEEI/NESN Jimmy Fund Radio-Telethon.
August 20, 2014Karen Perry, a patient at the Susan F. Smith Center for Women’s Cancers Gynecological Oncology program, who was diagnosed with ovarian cancer, talks about finding out that her son, Owen, was diagnosed with Acute Myeloid Leukemia shortly after her diagnosis, during the 13th annual WEEI/NESN Jimmy Fund Radio-Telethon.
July 14, 2014A study led by Dr. Joyce Liu showed that a combination of the PARP inhibitor olaparib plus the antiangiogenic cediranib nearly doubled progression-free survival for patients with certain types of recurrent ovarian cancer.
June 25, 2014Dr. Joyce Liu reported that in a Phase II clinical trial, a combination of olaparib (a drug that blocks DNA repair in cancer cells) and cediranib (which blocks blood vessel growth in tumors) was considerably more effective in women with recurrent ovarian cancer than olaparib alone.
May 31, 2014Significant improvement with the use of a combination drug therapy for recurrent ovarian cancer was reported at the annual meeting of the American Society of Clinical Oncology (ASCO) meeting. This is the first ovarian cancer study to use a combination of drugs that could be taken orally.
May 31, 2014Dr. Joyce Liu led a study showing a combination of two new pills may nearly double the length of survival for patients with recurrent ovarian cancer.
May 29, 2014Patients with non-metastatic ovarian cancer live an average of 16 months longer when chemotherapy is delivered into the abdomen instead of by standard intravenous infusion, yet only a minority of eligible patients are receiving it, report scientists from Dana-Farber Cancer Institute.
May 29, 2014A two-drug combination that disrupts critical signaling circuits in cancer cells has produced an observable benefit in patients with recurrent high-grade serous ovarian cancer (HGSC) or triple-negative breast cancer (TNBC).
March 17, 2014Dr. Alexi Wright says that a DNA test should be the primary screening tool for cervical cancer, due to the high rates of false negative results with the traditional Pap smear test.
March 11, 2014Dr. Alexi Wright comments on a new report that suggestions a connection between obesity and a woman's risk of ovarian cancer.
February 24, 2014Dr. Ursula Matulonis comments on a new study suggesting that women with the BRCA gene remove their ovaries by age 35.
February 11, 2014Following radiation treatment or surgery to remove lymph nodes (lymphadenectomy), patients can develop lymphedema, a condition that involves abnormal swelling, usually in the arms or the legs, due to an accumulation of lymphatic fluids. This fluid buildup is caused by blockage or removal of lymph nodes or lymph vessels.
January 6, 2014Approximately 10,000-11,000 women in the U.S. are diagnosed with cervical cancer every year. But with women having regular cervical cancer screenings, incidence and death rates from the disease have decreased by at least 80 percent in the U.S.
November 13, 2013More than 250 women business and community leaders will gather for the fifth Susan. F. Smith Center for Women's Cancers Executive Council, Beyond Boston Luncheon. The luncheon will include a panel discussion led by Eric P. Winer.
May 8, 2013A new study co-authored by Dr. Rameen Beroukhim may enable researchers to identify biological pathways that lead to endometrial cancer, as well as possible approaches to treatment.
April 13, 2013Dr. Joyce Liu presented findings at the AACR annual meeting from a study focused on an experimental vaccine aimed at treating women with ovarian cancer.
All gynecologic cancers news releases >>
All gynecologic cancers media coverage >>
All gynecologic cancers blog posts >>
Support Research and Treatment at the Susan F. Smith Center
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: